PLCδ1 activators would refer to a class of compounds that specifically target and modulate the activity of phospholipase C delta 1 (PLCδ1), which is an enzyme that plays a crucial role in intracellular signaling pathways. PLCδ1 is involved in the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into two secondary messengers, inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), upon activation by various stimuli. These secondary messengers subsequently participate in the regulation of diverse cellular processes such as cell proliferation, differentiation, and motility. Activators of PLCδ1 would be designed to enhance the activity of this enzyme, potentially by increasing its affinity for PIP2, stabilizing the active conformation of the enzyme, or facilitating its interaction with cofactors and membranes. The chemical structures of PLCδ1 activators could vary widely, potentially including small organic molecules, peptides, or lipid-like compounds that mimic the natural activators of PLCδ1 or otherwise promote its activation.
The investigation and characterization of PLCδ1 activators would require a range of biochemical and biophysical techniques. Functional assays to measure PLCδ1 activity, such as those monitoring the release of inorganic phosphate during PIP2 hydrolysis, would be fundamental in identifying and validating the activity of these compounds. Additionally, fluorescence-based assays could be employed to track the generation of IP3 and DAG in real-time, providing further insight into the efficacy of potential activators. To elucidate the mechanism by which these activators interact with PLCδ1, structural studies using X-ray crystallography, cryo-electron microscopy, or NMR spectroscopy could be conducted. Such studies would reveal the binding sites of activators on PLCδ1 and the conformational changes induced by activator binding. This structural information would be invaluable for the rational design and optimization of PLCδ1 activators, allowing for precise modifications to improve specificity and binding affinity. Computational modeling would augment these experimental approaches, enabling the prediction of how different chemical structures might interact with PLCδ1 and influence its enzymatic activity. It is important to note that, as of the latest available knowledge, PLCδ1 activators are not a recognized class of compounds in the scientific literature, and the above description is a theoretical framework based on general enzymatic activation principles.
SEE ALSO...
Items 1 to 10 of 19 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
A calcium ionophore that increases intracellular calcium concentration. Elevated calcium can activate PLC δ1, as calcium is a cofactor for its activation. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
An inhibitor of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump, leading to increased cytosolic calcium levels. Elevated calcium can activate PLC δ1. | ||||||
(+)-cis,trans-Abscisic acid | 21293-29-8 | sc-202103 sc-202103A | 500 µg 1 mg | $105.00 $188.00 | ||
TNF-α activates NF-κB signaling, which may increase PLCδ1 expression as part of the inflammatory response. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
Another calcium ionophore, similar to Ionomycin, which increases intracellular calcium levels and could thereby activate PLC δ1. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $449.00 | 61 | |
A cell-permeable calcium chelator that, upon hydrolysis in the cell, binds to calcium and increases its concentration. This increase in calcium can activate PLC δ1. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium is known to affect inositol monophosphatase, which could result in upregulated PLCδ1 expression to compensate for inositol depletion. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA activates protein kinase C (PKC) and might enhance PLCδ1 expression to sustain the required PIP2 hydrolysis for PKC activation. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
By increasing cAMP levels, Forskolin can activate protein kinase A (PKA) which may lead to upregulation of PLCδ1 in a signaling cascade. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid regulates gene expression through nuclear receptors, which could include transcriptional control of the PLCδ1 gene. | ||||||
Cholecalciferol | 67-97-0 | sc-205630 sc-205630A sc-205630B | 1 g 5 g 10 g | $70.00 $160.00 $290.00 | 2 | |
Vitamin D3, via its active metabolite, can modulate gene expression, potentially increasing PLCδ1 levels to affect cellular signaling. | ||||||